Text-mining applied to autoimmune disease research: the Sjögren’s syndrome knowledge base by Sven-Ulrik Gorr et al.
Gorr et al. BMC Musculoskeletal Disorders 2012, 13:119
http://www.biomedcentral.com/1471-2474/13/119RESEARCH ARTICLE Open AccessText-mining applied to autoimmune disease
research: the Sjögren’s syndrome knowledge base
Sven-Ulrik Gorr1*, Trevor J Wennblom2, Steve Horvath3, David TW Wong4 and Sara A Michie5Abstract
Background: Sjögren’s syndrome is a tissue-specific autoimmune disease that affects exocrine tissues, especially
salivary glands and lacrimal glands. Despite a large body of evidence gathered over the past 60 years, significant
gaps still exist in our understanding of Sjögren’s syndrome. The goal of this study was to develop a database that
collects and organizes gene and protein expression data from the existing literature for comparative analysis with
future gene expression and proteomic studies of Sjögren’s syndrome.
Description: To catalog the existing knowledge in the field, we used text mining to generate the Sjögren’s
Syndrome Knowledge Base (SSKB) of published gene/protein data, which were extracted from PubMed using text
mining of over 7,700 abstracts and listing approximately 500 potential genes/proteins. The raw data were manually
evaluated to remove duplicates and false-positives and assign gene names. The data base was manually curated to
477 entries, including 377 potential functional genes, which were used for enrichment and pathway analysis using
gene ontology and KEGG pathway analysis.
Conclusions: The Sjögren’s syndrome knowledge base (http://sskb.umn.edu) can form the foundation for an
informed search of existing knowledge in the field as new potential therapeutic targets are identified by
conventional or high throughput experimental techniques.Background
Sjögren’s syndrome is a tissue-specific autoimmune dis-
ease that affects exocrine tissues, especially salivary
glands and lacrimal glands. It is one of the most common
autoimmune disorders in the U.S., with an estimated
prevalence of 2–4 million people. The autoimmune-
mediated damage of the salivary and lacrimal glands in
Sjögren’s syndrome leads to a decrease in the produc-
tion of saliva and tears and to the development of dry
mouth and dry eyes. Without the lubricating and pro-
tective functions of saliva and tears, the oral and ocular
surfaces are subject to infections and discomfort, lead-
ing to a significantly reduced quality of life [1,2].
Development of Sjögren’s syndrome requires a com-
plex interplay between a number of genetic, hormonal
and environmental factors, most of which have not been
defined. Genetic linkages, especially involving major* Correspondence: sugorr@umn.edu
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reproduction in any medium, provided the orhistocompatibility complex (MHC) genes, have been
reported for Sjögren’s syndrome but it is not clear if, or
how, the associated genes are involved in the develop-
ment of the disease [3]. Additional non-MHC genes
have also been linked with the development of Sjögren’s
syndrome.
In addition to genetic predisposition, some studies
suggest that infection of a genetically-susceptible indi-
vidual by a virus or other pathogen might trigger the de-
velopment of an autoimmune disease [4]. The proposed
mechanisms include activation of the innate immune
system, release of self antigens from damaged or apop-
totic tissues, and molecular mimicry that results in acti-
vation of T cells and/or B cells that react with tissue
antigens [4].
Both the innate and the adaptive immune systems are
involved in the pathogenesis of Sjögren’s syndrome. The
type I interferon (IFN) pathway, which plays an import-
ant role in the innate immune response to viruses, is
also thought to play an important role in the develop-
ment of Sjögren’s syndrome and other autoimmune dis-
orders, including SLE [5,6]. Moreover, type I IFNs cand. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to IFN receptors on antigen presenting cells, T cells and
B cells, or indirectly, by inducing the production and re-
lease of cytokines and chemokines that bind to these
cells.
Autoantibodies to intracellular antigens, notably the
nuclear proteins SSA/Ro and SSB/La, are found in the
sera of many patients with Sjögren’s syndrome. These
autoantibodies are thought to develop when intracellular
antigens, some of which have undergone proteolytic
cleavage that reveals new antigenic epitopes, become
“visible” to the immune system in membrane blebs on
the surface of apoptotic cells [7]. Alternatively, antigenic
epitopes from bacteria and viruses, including Epstein-
Barr virus (EBV) and coxsackie virus, may act as
molecular mimics that trigger the development of anti-
bodies that cross react with similar epitopes on target
tissue autoantigens [2,8,9]. Although autoantibodies to
intracellular antigens are useful in the diagnosis of
Sjögren’s syndrome, it is not clear if they play a direct
role in the development of salivary gland and lacrimal
gland damage and hypofunction. In contrast, autoanti-
bodies to the M3 muscarinic acetylcholine receptor
(M3R) have been directly implicated in salivary gland
hypofunction in the nonobese diabetic (NOD) mouse
model of Sjögren’s syndrome [10]. Importantly, function-
inhibiting anti-M3R autoantibodies are found in the sera
of many patients with Sjögren’s syndrome [11].
Current therapy for Sjögren’s syndrome usually con-
sists of palliative treatment that relieves the symptoms
of dry eye and dry mouth, but fails to modify the under-
lying disease. Novel disease-modifying treatment strat-
egies, based on recent immunological insights in
Sjögren's syndrome and other autoimmune diseases,
have met with mixed results [12]. For example, in recent
clinical trials, treatment of Sjögren's syndrome patients
with a B cell-depleting anti-CD20 monoclonal antibody
(rituximab) led to significant improvement of the stimu-
lated whole saliva flow rate and a reduction in parotid
gland inflammation [13]. In contrast, TNFα inhibitors
have been ineffective in the treatment of Sjögren's syn-
drome. Detailed studies on the immune response in
Sjögren’s syndrome patients treated with one of the inhi-
bitors (etanercept) revealed an increase in the circulating
levels of TNFα [14]. These results suggest that TNFα
may not play a pivotal role in the disease and that other
therapeutic targets must be identified.
Despite a large body of evidence gathered over the
past 60 years, significant gaps still exist in our under-
standing of Sjögren’s syndrome. Recent gene expression
and proteomic studies have identified many genes and
pathways that may play a role in the pathogenesis of
Sjögren’s syndrome [15-17]. However, validation of these
data will require significant additional effort. As aninitial step in this validation, we have compiled the pub-
lished data on Sjögren’s syndrome that is not derived
from gene expression or proteomic studies. No such
unifying database currently exists. Through data cur-
ation, the existing data have been uniformly formatted
to allow systematic retrieval and comparisons to newly
generated gene expression data. As an example of its
functionality, the Sjögren's Syndrome Knowledge Base
(SSKB) was analyzed for biological functions and path-
ways that are likely to play a role in the disease.
Construction and content
Data mining
To catalog the existing knowledge in the field, we used
text mining to generate the Sjögren’s Syndrome Know-
ledge Base (SSKB) of published gene/protein data
(http://sskb.umn.edu/) [18]. The focus of this data-base
is on individually identified genes and proteins. Thus,
microarray experiments were not included. The raw data
for SSKB was extracted from PubMed [19]) using the
text mining program EBIMed (http://www.ebi.ac.uk/
Rebholz-srv/ebimed/) [20] with the search term "Sjo-
gren's Syndrome" restricted to "MeshHeadingsList". The
foundational search identified over 7,700 abstracts and
approximately 500 potential genes/proteins. The SSKB is
continually updated by regular automated searches of
PubMed followed by manual curation.
Curation of raw data
The identified abstracts were manually evaluated to re-
move duplicates and false-positives. In older publica-
tions, where gene names were not readily identifiable,
names were assigned based on in depth evaluation of
the protein name context and available gene data in
public databases, including the National Center for Bio-
technology Information’s Entrez search engine [21] and
UniProt [22,23]. The SSKB includes data from human
studies and animal models. For the genes identified in
animal models, the human homolog was identified by
automated ortholog search, using WebGestalt 2.0
[24,25]. These steps reduced the database to 477 current
entries. The online database contains the fully curated
data and currently contains 413 entries, which can be
accessed at http://sskb.umn.edu. Updates and newly
curated data are continually added.
The 477 entries were sorted to identify autoantigens
and viral/bacterial antigens, resulting in 377 potential
functional genes, which were used for enrichment and
pathway analysis.
Enrichment analysis
The 377 human gene entries were used for subsequent
enrichment analyses in Webgestalt [24,25]. Gene enrich-
ment in the SSKB gene set was compared to the human
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adjustment [26] and a significance level of P <0.01.
The Gene Ontology [27,28] was accessed with Web-
gestalt and analysis was restricted to processes and func-
tions represented by two or more genes. Pathway
analysis was performed with Webgestalt in the Kyoto
Encyclopedia of Genes and Genomes (KEGG) [29,30].
The selection was restricted to pathways with 4 or more
genes represented, resulting in identification of 72
KEGG pathways. The “salivary secretion” pathway
(KO04970) was recently added to KEGG (11/9/10) and
was not included in this analysis. This pathway contains
59 genes, seven of which are found in the SSKB gene
set.
Utility and discussion
We constructed a database containing proteins and
genes associated with Sjögren’s syndrome in human dis-
ease or animal models, as identified by text mining of
published data. The public SSKB currently contains 413
genes/proteins and can be viewed online (http://sskb.
umn.edu/). All genes have been assigned gene symbols
and UniProt IDs, which allows rapid retrieval of gene-
specific data from external databases. The SSKB data
base can be used to determine whether a list of genes is
enriched with known Sjögren’s syndrome genes and one
can carry out a function enrichment analysis (hypergeo-
metric distribution). Individual genes and the corre-
sponding gene products, synonyms and alternate names
can be searched by using a web browser search function.
Autoantigens, viral antigens and bacterial antigens are
separately identified under “Antigens”. The SSKB is con-
tinually maintained and updated and new genes are
added as their analysis is completed.
Based on the abstracts used to retrieve the SSKB
genes/proteins, 85 proteins were initially characterized
as autoantigens and 15 proteins were characterized as
viral (14) or bacterial (1) antigens. Not surprisingly,
SSA/Ro and SSB/La were among the most frequently
retrieved autoantigens. It has been proposed that viral or
bacterial antigens act as autoimmune triggers by mo-
lecular mimicry of endogenous human proteins [2,8,9].
However, eight of the 14 putative viral antigens in SSKB
were selected for BLAST analysis, which did not identify
strong sequence similarity with human proteins (not
shown).
The 377 proteins not identified as autoantigens or mi-
crobial antigens were considered candidates for func-
tional genes that could play a role in the initiation and
progression of Sjögren’s syndrome. Since the gene list
contains data from humans and animals, the corre-
sponding human genes were identified, with the assump-
tion that genes identified in animal models of Sjögren’s
syndrome may also be involved in the human disease.Gene ontology
The Gene Ontology database [27] was queried to iden-
tify the biological processes, cellular components and
molecular functions associated with genes in the SSKB
(Table 1). The 40 most highly enriched entries were
identified in each category.
The most highly enriched biological processes (19 of
40; 18 of the top 20) were associated with immune func-
tion, including leukocyte proliferation, leukocyte activa-
tion, and regulation of the immune response. Other
prominent biological processes were associated with
apoptosis and cell death. Thus, the SSKB data set is con-
sistent with recent microarray data [16] and reflects
current models for the biological processes involved in
the pathogenesis of Sjögren's syndrome [5,31,32].
The most highly enriched cellular component was the
calcineurin complex, which plays a major role in the ac-
tivation of T cells. Interestingly, in placebo-controlled
clinical trials, treatment of Sjögren’s syndrome patients
with eye drops that contain the calcineurin inhibitor
cyclosporine, led to significant improvement in several
of the signs and symptoms of dry eye [33].
Other highly enriched cellular components include: 1)
platelet alpha granules. Although platelet activation has
been reported in the salivary glands of Sjögren's syndrome
patients [34], a direct search of PubMed for “platelet alpha
granules” with “sjogren’s” did not retrieve any published
studies. Thus, while the proteins identified were retrieved
from the literature, their potential association with platelet
alpha granules in Sjögren’s syndrome has not previously
been noted. 2) MHC protein complexes were identified
and are presumably involved in the presentation of auto-
antigens [16]. 3) The finding that protein-lipid complexes
and lipoprotein particles are associated with Sjögren's syn-
drome may be consistent with changes in serum lipid
levels in Sjögren's syndrome patients [35] although the
prevalence of anti-phospholipid antibodies is low in Sjö-
gren's syndrome [36]. 4) Nerve terminals and axons were
also prominent cellular components, consistent with the
known neurological component of Sjögren's syndrome
[37].
In molecular function, nitric oxide synthase (NOS) ac-
tivity was the most highly enriched, although only three
genes (NOS1-3) were identified. Nitric oxide (NO) sig-
naling appears to be directly affected in salivary and lac-
rimal glands in Sjögren’s syndrome [38]. Other highly
enriched molecular functions include chemokine and
cytokine activity/receptor binding (8 of the top 15) and
peptidase activities.
Pathway analysis
The SSKB gene list was submitted to KEGG [29] to
identify biological pathways potentially associated with
Sjögren’s syndrome. A total of 72 KEGG pathways
Table 1 Gene Ontology enrichment analysis
Rank BIOLOGICAL PROCESS GO ID Reference Genes Observed Genes Ratio
1 regulation of lymphocyte proliferation GO:0050670 81 32 39.51%
2 regulation of leukocyte proliferation GO:0070663 82 32 39.02%
3 regulation of mononuclear cell proliferation GO:0032944 82 32 39.02%
4 adaptive immune response based on somatic
recombination of immune receptors built from
immunoglobulin superfamily domains
GO:0002460 112 38 33.93%
5 adaptive immune response GO:0002250 113 38 33.63%
6 lymphocyte proliferation GO:0046651 112 37 33.04%
7 leukocyte proliferation GO:0070661 114 37 32.46%
8 mononuclear cell proliferation GO:0032943 114 37 32.46%
9 regulation of lymphocyte activation GO:0051249 141 42 29.79%
10 regulation of cell activation GO:0050865 168 46 27.38%
11 regulation of leukocyte activation GO:0002694 159 43 27.04%
12 positive regulation of immune system process GO:0002684 229 60 26.20%
13 regulation of immune response GO:0050776 218 54 24.77%
14 immune effector process GO:0002252 200 45 22.50%
15 regulation of immune system process GO:0002682 362 79 21.82%
16 lymphocyte activation GO:0046649 272 59 21.69%
17 leukocyte activation GO:0045321 324 66 20.37%
18 inflammatory response GO:0006954 359 71 19.78%
19 cell activation GO:0001775 366 71 19.40%
20 immune response GO:0006955 750 133 17.73%
21 regulation of response to stimulus GO:0048583 441 75 17.01%
22 defense response GO:0006952 657 100 15.22%
23 immune system process GO:0002376 1066 162 15.20%
24 response to wounding GO:0009611 560 85 15.18%
25 response to external stimulus GO:0009605 904 110 12.17%
26 multi-organism process GO:0051704 668 79 11.83%
27 regulation of programmed cell death GO:0043067 812 92 11.33%
28 regulation of apoptosis GO:0042981 805 91 11.30%
29 regulation of cell death GO:0010941 815 92 11.29%
30 regulation of cell proliferation GO:0042127 739 79 10.69%
31 apoptosis GO:0006915 1063 102 9.60%
32 programmed cell death GO:0012501 1071 102 9.52%
33 response to chemical stimulus GO:0042221 1243 117 9.41%
34 cell proliferation GO:0008283 1056 98 9.28%
35 death GO:0016265 1171 107 9.14%
36 cell death GO:0008219 1167 106 9.08%
37 response to stress GO:0006950 1696 144 8.49%
38 positive regulation of biological process GO:0048518 1865 153 8.20%
39 positive regulation of cellular process GO:0048522 1699 130 7.65%
40 response to stimulus GO:0050896 3471 221 6.37%
Rank CELLULAR COMPONENT GO ID Count Observed Ratio
1 calcineurin complex GO:0005955 5 3 60.00%
2 external side of plasma membrane GO:0009897 131 40 30.53%
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Table 1 Gene Ontology enrichment analysis (Continued)
3 platelet alpha granule lumen GO:0031093 41 12 29.27%
4 MHC class II protein complex GO:0042613 14 4 28.57%
5 nerve terminal GO:0043679 14 4 28.57%
6 cytoplasmic membrane-bounded vesicle lumen GO:0060205 44 12 27.27%
7 vesicle lumen GO:0031983 46 12 26.09%
8 integrin complex GO:0008305 29 7 24.14%
9 platelet alpha granule GO:0031091 52 12 23.08%
10 high-density lipoprotein particle GO:0034364 24 5 20.83%
11 MHC protein complex GO:0042611 38 7 18.42%
12 plasma lipoprotein particle GO:0034358 34 6 17.65%
13 protein-lipid complex GO:0032994 34 6 17.65%
14 cell surface GO:0009986 305 51 16.72%
15 axon part GO:0033267 48 7 14.58%
16 extracellular space GO:0005615 670 84 12.54%
17 receptor complex GO:0043235 113 13 11.50%
18 secretory granule GO:0030141 174 19 10.92%
19 membrane raft GO:0045121 131 14 10.69%
20 extracellular region part GO:0044421 939 94 10.01%
21 axon GO:0030424 148 14 9.46%
22 cell soma GO:0043025 155 13 8.39%
23 soluble fraction GO:0005625 297 24 8.08%
24 cytoplasmic vesicle part GO:0044433 177 13 7.34%
25 extracellular region GO:0005576 1984 143 7.21%
26 basolateral plasma membrane GO:0016323 190 13 6.84%
27 lysosome GO:0005764 206 14 6.80%
28 integral to plasma membrane GO:0005887 1183 72 6.09%
29 intrinsic to plasma membrane GO:0031226 1206 73 6.05%
30 cytoplasmic membrane-bounded vesicle GO:0016023 537 32 5.96%
31 membrane-bounded vesicle GO:0031988 555 32 5.77%
32 extracellular matrix GO:0031012 335 19 5.67%
33 neuron projection GO:0043005 318 18 5.66%
34 plasma membrane part GO:0044459 1918 104 5.42%
35 cell fraction GO:0000267 1039 55 5.29%
36 cytoplasmic vesicle GO:0031410 628 33 5.25%
37 vesicle GO:0031982 655 33 5.04%
38 insoluble fraction GO:0005626 803 34 4.23%
39 plasma membrane GO:0005886 3650 139 3.81%
40 cytosol GO:0005829 1251 47 3.76%
Rank MOLECULAR FUNCTION GO ID COUNT Observed RATIO
1 arginine binding GO:0034618 3 3 100.00%
2 nitric-oxide synthase activity GO:0004517 3 3 100.00%
3 tetrahydrobiopterin binding GO:0034617 3 3 100.00%
4 C-X-C chemokine binding GO:0019958 8 4 50.00%
5 beta-amyloid binding GO:0001540 13 5 38.46%
6 tumor necrosis factor receptor binding GO:0005164 21 8 38.10%
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7 chemokine activity GO:0008009 47 17 36.17%
8 chemokine receptor binding GO:0042379 49 17 34.69%
9 coreceptor activity GO:0015026 19 6 31.58%
10 tumor necrosis factor receptor superfamily binding GO:0032813 31 9 29.03%
11 cytokine receptor binding GO:0005126 178 46 25.84%
12 chemokine binding GO:0019956 26 6 23.08%
13 cytokine activity GO:0005125 196 45 22.96%
14 growth factor receptor binding GO:0070851 67 14 20.90%
15 collagen binding GO:0005518 35 7 20.00%
16 G-protein-coupled receptor binding GO:0001664 107 20 18.69%
17 integrin binding GO:0005178 58 9 15.52%
18 cysteine-type endopeptidase activity GO:0004197 71 10 14.08%
19 growth factor activity GO:0008083 161 19 11.80%
20 cytokine binding GO:0019955 108 12 11.11%
21 protein heterodimerization activity GO:0046982 189 21 11.11%
22 glycosaminoglycan binding GO:0005539 139 14 10.07%
23 protein complex binding GO:0032403 196 19 9.69%
24 receptor binding GO:0005102 856 83 9.70%
25 receptor signaling protein activity GO:0005057 159 15 9.43%
26 pattern binding GO:0001871 153 14 9.15%
27 peptidase inhibitor activity GO:0030414 154 14 9.09%
28 carbohydrate binding GO:0030246 349 29 8.31%
29 endopeptidase activity GO:0004175 370 28 7.57%
30 polysaccharide binding GO:0030247 153 14 9.15%
31 protein dimerization activity GO:0046983 514 36 7.00%
32 identical protein binding GO:0042802 618 38 6.15%
33 enzyme binding GO:0019899 505 29 5.74%
34 peptidase activity GO:0008233 563 30 5.33%
35 peptidase activity, acting on L-amino acid peptides GO:0070011 546 29 5.31%
36 molecular transducer activity GO:0060089 2116 98 4.63%
37 signal transducer activity GO:0004871 2116 98 4.63%
38 receptor activity GO:0004872 1674 71 4.24%
39 protein binding GO:0005515 8041 280 3.48%
40 binding GO:0005488 12465 320 2.57%
The table ranks the gene enrichment in biological processes, cellular component and molecular function with corresponding GO IDs. For each GO ID, the number of
Observed Genes identified in the SSKB was divided by the number of Reference Genes in the human genome to calculate the Ratio of enrichment (Ratio).
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analysis (Table 2).
The pathway analysis revealed dominant pathways asso-
ciated with immune regulation. Indeed, the eight most
highly enriched pathways were associated with antigen
presenting cells and activation of T cells and B cells.
Several cancer associated pathways were identified.
This is partly due to the overlap between cancer path-
ways. These pathways typically include cytokine orgrowth factor stimulation of cell cycle and cell death and
were not further analyzed.
Pathways associated with apoptosis, cytokine signaling
and inflammation were also highly enriched. To focus on
the events associated with initiation of Sjögren's syn-
drome, we analyzed pathways with known triggers. Several
of the highly enriched pathways are triggered by bacterial
toxins, viral DNA, or viral RNA. These include signaling
pathways for Toll-like receptor, NOD-like receptor, RIG-I-
Table 2 Biological pathways associated with SSKB genes
Rank PATHWAY SSKB Genes ENRICHMENT Raw P Adjust P
1 Allograft rejection 23 76.02 3.62E-39 6.82E-38
2 Intestinal immune network for IgA production 27 67.82 7.26E-44 2.05E-42
3 Asthma 14 58.61 4.14E-22 2.75E-21
4 Type I diabetes mellitus 20 57.09 9.13E-31 9.38E-30
5 Graft-versus-host disease 18 53.83 3.21E-27 2.79E-26
6 Autoimmune thyroid disease 22 52.13 1.29E-32 1.82E-31
7 Primary immunodeficiency 14 50.24 6.38E-21 3.79E-20
8 Hematopoietic cell lineage 33 47.1 1.39E-46 5.24E-45
9 Toll-like receptor signaling pathway 37 46.01 1.13E-51 6.38E-50
10 Apoptosis 25 35.68 5.55E-32 6.97E-31
11 NOD-like receptor signaling pathway 17 34.44 7.61E-22 4.78E-21
12 Amyotrophic lateral sclerosis (ALS) 14 33.18 5.81E-18 2.85E-17
13 Other glycan degradation 4 31.4 6.67E-06 1.24E-05
14 Cytokine-cytokine receptor interaction 66 31.05 5.91E-79 6.68E-77
15 T cell receptor signaling pathway 26 30.24 4.12E-31 4.66E-30
16 RIG-I-like receptor signaling pathway 17 30.07 9.98E-21 5.64E-20
17 Cell adhesion molecules (CAMs) 32 29.99 6.40E-38 1.03E-36
18 Bladder cancer 10 29.9 1.06E-12 3.24E-12
19 Viral myocarditis 17 29.25 1.68E-20 9.04E-20
20 Cytosolic DNA-sensing pathway 13 29.16 5.78E-16 2.42E-15
21 Pancreatic cancer 15 26.17 1.88E-17 8.50E-17
22 Small cell lung cancer 16 23.92 7.32E-18 3.45E-17
23 Glycosaminoglycan degradation 4 23.92 2.13E-05 3.65E-05
24 Natural killer cell mediated cytotoxicity 25 22.92 1.06E-26 8.56E-26
25 ErbB signaling pathway 13 22.16 2.51E-13 8.86E-13
26 Epithelial cell signaling in Helicobacter pylori infection 12 22.16 2.64E-13 9.04E-13
27 Complement and coagulation cascades 12 21.84 3.17E-13 1.05E-12
28 B cell receptor signaling pathway 13 21.77 3.38E-14 1.23E-13
29 Prion diseases 6 21.53 3.27E-07 6.84E-07
30 Antigen processing and presentation 15 21.17 5.49E-16 2.39E-15
31 Colorectal cancer 14 20.93 6.14E-15 2.48E-14
32 Adipocytokine signaling pathway 11 20.62 6.05E-12 1.80E-11
33 Chemokine signaling pathway 30 19.83 7.80E-30 7.35E-29
34 Prostate cancer 14 19.76 1.42E-14 5.53E-14
35 Glioma 10 19.32 1.10E-10 2.89E-10
36 Jak-STAT signaling pathway 23 18.64 1.67E-22 1.18E-21
37 Non-small cell lung cancer 8 18.61 1.13E-08 2.50E-08
38 Melanoma 10 17.69 2.71E-10 6.96E-10
39 Pathways in cancer 46 17.51 9.85E-43 2.23E-41
40 Fc epsilon RI signaling pathway 11 17.49 3.90E-11 1.05E-10
41 Chronic myeloid leukemia 10 16.75 4.74E-10 1.19E-09
42 GnRH signaling pathway 12 14.92 3.42E-11 9.43E-11
43 Leukocyte transendothelial migration 14 14.9 7.91E-13 2.48E-12
44 VEGF signaling pathway 9 14.87 1.04E-08 2.35E-08
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45 Hypertrophic cardiomyopathy (HCM) 10 14.78 1.67E-09 4.10E-09
46 p53 signaling pathway 8 14.56 8.19E-08 1.75E-07
47 Endometrial cancer 6 14.49 3.65E-06 7.11E-06
48 Systemic lupus erythematosus 16 14.35 3.27E-14 1.23E-13
49 MAPK signaling pathway 30 14.01 3.15E-25 2.37E-24
50 Focal adhesion 22 13.75 1.21E-18 6.21E-18
51 Dilated cardiomyopathy 10 13.65 3.66E-09 8.44E-09
52 Type II diabetes mellitus 5 13.36 3.63E-05 6.12E-05
53 Neurotrophin signaling pathway 13 12.96 3.17E-11 8.96E-11
54 ECM-receptor interaction 8 11.96 3.85E-07 7.91E-07
55 Alzheimer's disease 16 11.89 6.32E-13 2.04E-12
56 Lysosome 11 11.81 2.86E-09 6.73E-09
57 Arginine and proline metabolism 5 11.63 7.15E-05 0.0001
58 Renal cell carcinoma 6 10.77 2.09E-05 3.63E-05
59 Long-term depression 6 10.77 2.09E-05 3.63E-05
60 Long-term potentiation 6 10.77 2.09E-05 3.63E-05
61 Proteasome 4 10.47 0.0006 0.0009
62 Progesterone-mediated oocyte maturation 7 10.22 6.00E-06 1.15E-05
63 TGF-beta signaling pathway 7 10.11 6.48E-06 1.22E-05
64 Regulation of actin cytoskeleton 16 9.3 2.69E-11 7.79E-11
65 Calcium signaling pathway 13 9.17 2.36E-09 5.67E-09
66 Wnt signaling pathway 11 9.15 4.17E-08 9.06E-08
67 Gap junction 6 8.37 8.67E-05 0.0001
68 Cell cycle 8 7.85 9.32E-06 1.70E-05
69 Oocyte meiosis 7 7.71 3.80E-05 6.31E-05
70 Axon guidance 7 6.82 8.33E-05 0.0001
71 Endocytosis 10 6.72 2.93E-06 5.81E-06
72 Metabolic pathways 26 2.96 1.12E-06 2.26E-06
The table lists the number of SSKB genes associated with individual KEGG pathways. The pathways are ranked according to their Enrichment relative to the number of
reference genes in the human genome based on the hypergeometric test. The raw P-values (hypergeometric test) and the multiple test-adjusted P-values are listed for
each pathway.
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Overlap with other autoimmune diseases
The KEGG pathways include several pathways for auto-
immune diseases, including type I diabetes mellitus,
autoimmune thyroid disease, and SLE. While about 50%
of the genes associated with the first two pathways are
also associated with Sjögren's syndrome, only 16 Sjö-
gren's syndrome genes were identified in the 140-gene
SLE pathway (KEGG ID: hsa05322). These findings sug-
gest that significant differences exist in the pathogenesis
of autoimmune diseases.
Conclusions
The results of this analysis can serve as a background
and comparison for the increasing number of geneexpression data sets available for Sjögren’s syndrome,
e.g. [15-17]. Preliminary analysis of such data sets sug-
gest that the biological pathways identified in the SSKB
are very similar to those identified in human parotid tissue
but quite different from those identified in human labial
salivary glands [15]. Future analyses will further define
these differences and focus on the comparison of bio-
logical pathways identified in human tissues and mouse
models of Sjögren’s syndrome. It is envisioned that the
SSKB data can also serve as the starting point for literature
reviews and literature-based validation of identified genes;
functional gene enrichment studies; protein-protein inter-
action networks and other bioinformatics analyses; it can
be used to arrive at gene sets for SNP set enrichment ana-
lysis (pathway based GWAS studies); it can be used to
define a gene set for gene set enrichment analysis
(GSEA); as a starting point for bioinformatics analysis
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2 hybrid) can be identified among the SSKB genes.
Availability and requirements
The Sjögren’s syndrome knowledge base is freely avail-
able at sskb.umn.edu.
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